Skip to main content

RT @ericdeinmd: Conaghan: "Most promising study in OA" at #RNL2023 NGF inhibitor to OA had benefit, but very poorly tole

Social Author Name
Eric Dein
Tweet Content
Conaghan: "Most promising study in OA" at #RNL2023 NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated? Can there be sustained response. Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪 @RheumNow https://t.co/eBMEPBG9wn
Show on Archive Page
On
Display in Search Results
On
PDQ
Off